"The Lilly-TCS engagement will help us aggressively position as a full services player in the emerging life sciences and healthcare sector," N Chandrasekaran, executive VP, TCS, said.
Though TCS has not yet disclosed the size of the deal, analysts and investment bankers here said that the contract could be worth $35-40 million.
The deal is TCS's second pharma outsourcing contract. Last year, it had bagged a contract from Novo Nordisk for clinical trial data management.